Loading…
BioCryst Pharmaceuticals, Inc., a biotechnology company, developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated and seasonal influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat HAE. It is also developing BCX17725, a protein therapeutic for netherton syndrome which is in phase 1; Avoralstat, an ocular plasma kallikrein inhibitor for diabetic macular edema that is in Phase 1; Navenibart, a monoclonal antibody plasma kallikrein inhibitor for HAE which is in Phase 3; BCX17725, an investigational protein therapeutic KLK5 inhibitor for the treatment of netherton syndrome that is in phase 1 clinical trial; STAR-0310, a monoclonal antibody OX40 antagonist for the treatment of atopic dermatitis which is in Phase 1a trial. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd., Shionogi & Co., Ltd., and Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $875M | $348M | $264M | $345M | -221.4% | 94.1% | -396.9% |
| 2024 | $451M | $13M | $-89M | $-53M | 18.7% | 36.0% | -60.8% |
| 2023 | $331M | $-116M | $-227M | $-97M | 49.7% | 22.4% | -8.3% |
| 2022 | $271M | $-144M | $-247M | $-163M | 83.9% | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total Revenue | - | 270.83 | 331.41 | 450.71 | 874.84 |
| Operating Revenue | - | 270.83 | 331.41 | 450.71 | 874.84 |
| Cost Of Revenue | - | 6.59 | 4.48 | 12.27 | 19.08 |
| Gross Profit | - | 264.23 | 326.93 | 438.44 | 855.76 |
| Operating Expense | - | 412.67 | 430.64 | 440.99 | 514.77 |
| Research And Development | - | 253.30 | 216.57 | 174.64 | 166.13 |
| Selling General And Administration | - | 159.37 | 214.07 | 266.35 | 348.65 |
| Total Expenses | - | 419.26 | 435.12 | 453.26 | 533.85 |
| Operating Income | - | -148.44 | -103.71 | -2.54 | 340.99 |
| Total Operating Income As Reported | - | -148.44 | -103.71 | -2.54 | 340.99 |
| EBITDA | - | -143.85 | -116.34 | 12.81 | 347.65 |
| Normalized EBITDA | - | -141.87 | -86.28 | 13.45 | 365.14 |
| EBIT | - | -145.29 | -117.99 | 11.56 | 346.26 |
| Interest Income | - | 5.13 | 15.78 | 14.75 | 10.67 |
| Interest Expense | - | 99.09 | 108.24 | 98.52 | 78.87 |
| Net Interest Income | - | -93.96 | -92.46 | -83.77 | -68.20 |
| Other Non Operating Income Expenses | - | - | - | - | 12.09 |
| Other Income Expense | - | -1.98 | -30.06 | -0.64 | -5.39 |
| Interest Income Non Operating | - | 5.13 | 15.78 | 14.75 | 10.67 |
| Interest Expense Non Operating | - | 99.09 | 108.24 | 98.52 | 78.87 |
| Net Non Operating Interest Income Expense | - | -93.96 | -92.46 | -83.77 | -68.20 |
| Pretax Income | - | -244.38 | -226.23 | -86.95 | 267.39 |
| Tax Provision | - | 2.73 | 0.31 | 1.93 | 3.53 |
| Tax Rate For Calcs | - | 0 | 0 | 0 | 0 |
| Tax Effect Of Unusual Items | - | -0.42 | -6.31 | -0.13 | -0.17 |
| Net Income Continuous Operations | - | -247.12 | -226.54 | -88.88 | 263.86 |
| Net Income From Continuing And Discontinued Operation | - | -247.12 | -226.54 | -88.88 | 263.86 |
| Net Income From Continuing Operation Net Minority Interest | - | -247.12 | -226.54 | -88.88 | 263.86 |
| Net Income | - | -247.12 | -226.54 | -88.88 | 263.86 |
| Net Income Common Stockholders | - | -247.12 | -226.54 | -88.88 | 263.86 |
| Net Income Including Noncontrolling Interests | - | -247.12 | -226.54 | -88.88 | 263.86 |
| Normalized Income | - | -245.55 | -202.79 | -88.37 | 281.17 |
| Diluted NI Availto Com Stockholders | - | -247.12 | -226.54 | -88.88 | 263.86 |
| Basic Average Shares | - | 185.91 | 192.20 | 206.70 | 209.89 |
| Diluted Average Shares | - | 185.91 | 192.20 | 206.70 | 218.58 |
| Reconciled Depreciation | - | 1.44 | 1.66 | 1.25 | 1.39 |
| Reconciled Cost Of Revenue | - | 6.59 | 4.48 | 12.27 | 19.08 |
| Total Unusual Items | - | -1.98 | -30.06 | -0.64 | -17.48 |
| Total Unusual Items Excluding Goodwill | - | -1.98 | -30.06 | -0.64 | -17.48 |
| Special Income Charges | - | 0 | -29.02 | 0 | -17.33 |
| Other Special Charges | -55.84 | - | 29.02 | - | 17.33 |
| Gain On Sale Of Security | - | -1.98 | -1.04 | -0.64 | -0.15 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| BioCryst Pharmaceuticals, Inc.this co. | BCRX | $2.2B | 8.16 | -18.07 | -221.4% | 7.20 |
| Immunome, Inc. | IMNM | $2.2B | -10.49 | 3.51 | -33.5% | -7.14 |
| Mineralys Therapeutics, Inc. | MLYS | $2.2B | -14.28 | 3.41 | -23.9% | - |
| Enliven Therapeutics, Inc. | ELVN | $2.2B | -20.85 | 4.70 | -22.6% | -17.28 |
| Kodiak Sciences Inc. | KOD |
| 2021 |
| - |
| - |
| - |
| - |
| - |
| - |
| - |
| $2.1B |
| - |
| 13.58 |
| -146.1% |
| - |
| Aurinia Pharmaceuticals Inc. | AUPH | $2.1B | 7.33 | 3.62 | 49.4% | 15.22 |
| Clover Health Investments, Corp. | CLOV | $2.1B | -24.56 | 6.81 | -27.7% | - |
| NovoCure Limited | NVCR | $2.1B | - | 6.12 | -40.0% | - |
| Intellia Therapeutics, Inc. | NTLA | $2.1B | - | 3.07 | -61.5% | - |
| Peer Median | - | -14.28 | 4.16 | -30.6% | -7.14 | |